Hims & Hers Health, INC 8-K filings

Hims & Hers Health, Inc. announced the resignation of its Chief Accounting Officer, Irene Becklund, effective October 9, 2026, with an advisory role continuing until July 10, 2027.

Hims & Hers Health, Inc. has amended its credit agreement and entered into a Master Receivables Purchase Agreement, establishing a $400 million facility.

Hims & Hers Health, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026, where directors were elected and executive compensation was approved.

Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, significantly expanding its global consumer health platform and reinforcing its long-term financial targets.

Hims & Hers Health, Inc. has priced an upsized $350 million offering of 0.00% convertible senior notes due 2032 to fund international expansion and AI investments.

Hims & Hers Health, Inc. announced first quarter 2026 financial results, reporting revenue of $608 million, a 4% year-over-year increase, and nearly 2.6 million subscribers, while raising full-year revenue and Adjusted EBITDA guidance.

Hims & Hers Health, Inc. announced robust financial results for Q4 and full year 2025, with revenue up 59% year-over-year to $2.35 billion, driven by subscriber growth and strategic international expansion.

Hims & Hers Health, Inc. announced a definitive agreement to acquire Eucalyptus, an international digital health leader, for up to $1.15 billion to accelerate global expansion.

Hims & Hers Health, Inc. announced its Board of Directors authorized a new share repurchase program of up to $250 million of its Class A common stock.

Hims & Hers Health, Inc. reported robust third-quarter 2025 financial results, with revenue up 49% year-over-year and a narrowed full-year guidance, driven by subscriber growth and strategic expansion.

Hims & Hers Health, Inc. announced a leadership transition with Mike Chi appointed Chief Operating Officer, consolidating key functions, as Nader Kabbani moves to an advisory role.

Hims & Hers Health, Inc. clarifies official public communication channels for investors.

Hims & Hers Health, Inc. subsidiary Hims, Inc. has entered into a 15-year lease for a 352,012 square foot facility in New Albany, Ohio, for expanded operations.

Hims & Hers Health, Inc. reported robust second quarter 2025 financial results, with revenue up 73% year-over-year to $544.8 million, driven by a 31% increase in subscribers and strong adoption of personalized treatment plans.

Hims & Hers Health, Inc. announced that its stockholders approved all three proposals, including the election of directors, ratification of KPMG LLP, and advisory approval of executive compensation, at its Annual Meeting held on June 12, 2025.

Hims & Hers Health issues $1 billion in convertible senior notes due 2030, with a zero percent interest rate, to qualified institutional buyers.

Hims & Hers Health, Inc. will offer $870 million in convertible senior notes due 2030 to qualified institutional buyers to fund global expansion, AI development, and strategic acquisitions.

Hims & Hers Health, Inc. announced a strong first quarter in 2025, with revenue more than doubling and significant increases in net income and adjusted EBITDA.

Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc., will transition to an advisory role after a long career with the company.

Hims & Hers Health, Inc. announces impressive financial results for 2024, with revenue reaching $1.5 billion, a 69% increase year-over-year, driven by subscriber growth and the expansion of its weight loss offerings.

Hims & Hers Health, Inc. has increased its board size and appointed Deb Autor as a new independent director, effective immediately.

Hims & Hers Health, Inc. announced a 77% year-over-year revenue increase to $401.6 million, alongside a net income of $75.6 million and raised its full-year revenue and adjusted EBITDA guidance.

Hims & Hers Health, Inc. has registered 976,341 shares of Class A common stock for resale, following its acquisition of MedisourceRx.

Hims & Hers Health, Inc. announced a 52% year-over-year revenue increase to $315.6 million, along with net income of $13.3 million and raised full year guidance.

Hims & Hers Health, Inc. has increased its board size to nine directors and appointed Kre Schultz as a new independent director, effective immediately.

Hims & Hers Health, Inc. held its annual meeting on June 6, 2024, where stockholders voted on the election of directors, ratification of the company's accounting firm, and executive compensation.

Hims & Hers Health, Inc. has appointed Anja Manuel to the audit and risk committees of its board of directors, effective June 6, 2024.

Hims & Hers Health, Inc. announced a 46% year-over-year revenue increase to $278.2 million and a net income of $11.1 million for the first quarter of 2024, along with an increase to full year guidance.

Hims & Hers Health has increased its board size to eleven and appointed Anja Manuel as a new independent director, effective immediately.

Hims & Hers Health has appointed Christopher Payne to the compensation and risk committees of its board, effective June 6, 2024.